Plain-English translation of NCT07298408 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a pilot study testing cannabidiol (CBD)—a non-intoxicating compound derived from plants—to see if it can safely reduce nerve pain caused by type 2 diabetes. About 12 to 20 adults with mild to moderate nerve damage will participate. The medication is given as a liquid tincture, and researchers will measure whether it helps with pain and whether people can tolerate it well.
Nerve pain from diabetes is a serious and distressing problem that affects many people's quality of life, but current treatments mainly mask symptoms without stopping the underlying damage. This medication may work differently—by reducing inflammation and protecting nerve cells—so researchers want to test whether it could offer better relief.
You likely qualify if…
You likely don't qualify if…
You would participate in two 6-week treatment phases separated by a 2-week break. In one phase, you'll take the active medication (50 mg twice daily by mouth as a liquid); in the other phase, you'll take a placebo that looks and tastes identical—neither you nor the researchers will know which is which. You'll complete questionnaires about your pain and symptoms, and the study team will monitor how well you tolerate the treatment and whether it helps reduce your nerve pain.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States